Nomura Holdings Inc. Sells 2,681,754 Shares of Dynavax Technologies Corporation $DVAX

Key Points

• Nomura Holdings Inc. has reduced its holdings in Dynavax Technologies by 93.4%, selling over 2.6 million shares, while still holding approximately 0.16% of the company.
• Dynavax Technologies reported earnings of $0.14 per share for the last quarter, exceeding analysts' expectations, with revenues of $95.44 million compared to estimates of $87.55 million.
• Analysts have upgraded Dynavax, with Wall Street Zen moving it from a "hold" to a "buy" rating, and JMP Securities setting a target price of $32.00 for the stock.

Nomura Holdings Inc. cut its stake in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 93.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190,238 shares of the biopharmaceutical company's stock after selling 2,681,754 shares during the quarter. Nomura Holdings Inc. owned approximately 0.16% of Dynavax Technologies worth $2,467,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of DVAX. DekaBank Deutsche Girozentrale bought a new position in shares of Dynavax Technologies in the first quarter valued at about $30,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Dynavax Technologies by 5,485.7% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 2,304 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Dynavax Technologies in the fourth quarter valued at about $35,000. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 88.4% in the first quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after acquiring an additional 3,627 shares in the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new position in shares of Dynavax Technologies in the first quarter valued at about $131,000. 96.96% of the stock is owned by institutional investors.

Insider Buying and Selling at Dynavax Technologies

In related news, Director Scott Dunseth Myers purchased 3,800 shares of Dynavax Technologies stock in a transaction dated Friday, August 22nd. The shares were bought at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the purchase, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This trade represents a 12.18% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.98% of the company's stock.

Dynavax Technologies Price Performance

Shares of DVAX traded down $0.37 during mid-day trading on Monday, reaching $9.70. The company had a trading volume of 1,068,898 shares, compared to its average volume of 2,073,236. The company's 50 day simple moving average is $10.63 and its 200 day simple moving average is $11.19. Dynavax Technologies Corporation has a 1-year low of $9.22 and a 1-year high of $14.63. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -21.10 and a beta of 1.24.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The company had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. Analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DVAX shares. JMP Securities restated a "market outperform" rating and issued a $32.00 price target on shares of Dynavax Technologies in a research note on Friday, August 22nd. Wall Street Zen upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Dynavax Technologies has a consensus rating of "Moderate Buy" and a consensus price target of $24.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.